BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
Tasquinimod as an adjunct to immunotherapies administered peri-operatively
Tasquinimod as an adjunct to immunotherapies administered peri-operatively is a funding opportunity from BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, up to 129586, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY – PROJECT 2 Although immunotherapy has significantly improved patient survival for many types of cancers, to date no immunotherapeutic agent has shown consistent efficacy against glioblastoma (GBM). Many promising immunotherapy approaches for GBM are administered in the peri-operative period, but,…